Home / Pharmaceutical company intelligence
Pharmaceutical company intelligence

Arreta Pharmaceuticals (Pvt.) Ltd.

Private pharmaceutical manufacturer · Rawalpindi · Pakistan

Rawalpindi-based pharmaceutical manufacturer represented in DRAP GMP inspection records.

Sourced corporate profile Corporate identity fields are source-tracked; portfolio, price and competitor intelligence remains independently calculated by MedInfoBase.
ShareSend this page
Evidence & freshness

What is sourced, and how recent is it?

Public-source corporate details
Latest regulatory-source observation23 Sep 2026Newest linked source record observed by MedInfoBase
Latest portfolio source check9 Aug 2026Latest source-check date across this published portfolio
Latest effective price date23 Jul 2026Newest effective date among published current price records
Corporate profile evidence1 sourceCorporate source details checked 16 Aug 2026

Regulatory-source portfolio data and company-supplied/corporate profile fields are tracked separately. Company claim/verification status is separate from source quality. An unclaimed company can still have a fully official-source-observed portfolio.

Regulatory & corporate identity

Company profile

Public-source corporate details
Company type
Private pharmaceutical manufacturer
Address
Plot No. 13, Street No. N-5, RCCI Industrial Estate, Rawalpindi, Punjab, Pakistan
Corporate source details checked
16 Aug 2026
Corporate profile completeness
50%
DRAP manufacturing licenceAs published by the DRAP Licensing Division. DRAP issues this list for stakeholder review and states it is not a reference for litigation, claims or citation.
Formulation 000846 Arreta Pharmaceuticals (Pvt) Ltd. · Punjab
Source-linked licence identifiersShown as recorded in linked source rows; not a claim of current validity.
DML 000846 80 linked products · source seen 23 Sep 2026 View source ↗
Corporate profile source ledger Profile Source Url source ↗
Location intelligence

Company location

Google Maps
Location recorded

A sourced company location is recorded. Use the map link below for directions.

Open in Google Maps ↗
Intelligence snapshot

Portfolio at a glance

Not sales data · published MedInfoBase database view
Rx85public portfolio records represented
REG73unique registrations represented
IDX80indexed MedInfoBase presentations
SRC2additional source-observed presentations
R+3registry-only registrations
VER3registry-verified exact registrations
PKR80current validated price records
G34generic molecules in indexed catalogue
DF5dosage-form groups
TA9therapeutic areas
How to read these counts

RegistrationA unique regulatory registration number. One registration may have more than one strength/form/pack presentation.

PresentationA distinct medicine presentation, such as a particular strength, dosage form and pack.

IndexedA canonical MedInfoBase presentation that passed MedInfoBase identity and publication controls.

Source observedAn additional presentation observed in an official DRAP source but not counted as an indexed MedInfoBase presentation.

Registry onlyAn exact registry-verified registration not otherwise represented by an indexed or source-observed presentation.

Registry verifiedAn exact registration match found in an official DRAP registry source. This is evidence status, not a commercial ranking.

Data coverage

How complete is this profile?

Current price coverage94%
public portfolio presentations with a validated current price
Official-source coverage100%
products linked back to a source record
Unit-price parse coverage100%
priced packs safely normalized per unit
Comparable-market coverage99%
products with at least one like-for-like comparator
Therapeutic classification100%
products assigned to a broad therapeutic area
Visual intelligence

Downloadable company intelligence charts

Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.

Shareable intelligence

Therapeutic Portfolio Mix

Shows where the company portfolio is concentrated across broad therapeutic areas.

Therapeutic Portfolio MixArreta Pharmaceuticals (Pvt.) Ltd.Share of current product presentations by broad therapeutic areaMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/arreta-pharmaceuticals-pvt-ltdGenerated 25 Sep 2026Anti-infectives42 · 53%CNS & mental health17 · 21%Pain & musculoskeletal8 · 10%Gastrointestinal & hepatology5 · 6%Hematology & thrombosis3 · 4%Vitamins, minerals & nutrition2 · 3%Respiratory & allergy1 · 1%Other therapeutic areas2 · 3%Percentages are based on current product presentations in the MedInfoBase company portfolio.

Portfolio distribution, not sales or market-share data.

Shareable intelligence

Dosage Form Portfolio

Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.

Dosage Form PortfolioArreta Pharmaceuticals (Pvt.) Ltd.Distribution of current product presentations by normalized dosage formMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/arreta-pharmaceuticals-pvt-ltdGenerated 25 Sep 202680presentationsTablet39 · 49%Suspension16 · 20%Injection13 · 16%Capsule11 · 14%Syrup1 · 1%Dosage-form wording is normalized for intelligence display; original source wording remains preserved in product records.

Counts are product presentations, not production or sales volumes.

Shareable intelligence

Equivalent Price Position

Shows whether safely comparable products are below, near or above the peer median unit price.

Equivalent Price PositionArreta Pharmaceuticals (Pvt.) Ltd.Current company products compared with like-for-like equivalent medicines using normalized unit pricesMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/arreta-pharmaceuticals-pvt-ltdGenerated 25 Sep 202679comparable productsBelow peer median50 · 63%Near peer median25 · 32%Above peer median4 · 5%Company median price position-14.2%Lowest-price equivalents6Method: same generic + stated strength + dosage form + compatible unit basis; pack prices normalized per unit.

This is price-position intelligence, not sales, demand or market-share data.

Shareable intelligence

Closest Portfolio Competitors

Highlights other manufacturers with the greatest generic overlap with this company portfolio.

Closest Portfolio CompetitorsArreta Pharmaceuticals (Pvt.) Ltd.Companies with the largest number of shared generic medicines in the MedInfoBase databaseMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/arreta-pharmaceuticals-pvt-ltdGenerated 25 Sep 2026Mediate Pharmaceutical Pvt Ltd27 shared79% overlapNeutro Pharma (Pvt.) Ltd.,25 shared74% overlapSAFE PHARMACEUTICAL (PVT) LTD24 shared71% overlapGlobal Pharmaceuticals (Pvt.) Ltd.23 shared68% overlapSemos Pharmaceuticals PVT LTD23 shared68% overlapM/s. Genix Pharma (Pvt) Ltd.22 shared65% overlapPortfolio overlap measures shared generics only; it is not a measure of market share, affiliation or sales competition.

Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.

Portfolio intelligence

Therapeutic areas

Broad portfolio view

High-level clinical areas represented by this company’s current MedInfoBase portfolio.

Anti-infectives42 products · 53%
CNS & mental health17 products · 21%
Pain & musculoskeletal8 products · 10%
Gastrointestinal & hepatology5 products · 6%
Hematology & thrombosis3 products · 4%
Vitamins, minerals & nutrition2 products · 3%
Respiratory & allergy1 products · 1%
Reproductive & genitourinary1 products · 1%
Pharmacological detail

Drug classes

More specific view

More specific classes derived from the canonical generic and preserved curated classifications.

Third-generation cephalosporins17 products · 21%
Analgesics / NSAIDs8 products · 10%
Antiepileptics7 products · 9%
Fluoroquinolone antibacterials5 products · 6%
Antipsychotics5 products · 6%
Nitroimidazole anti-infectives5 products · 6%
Benzodiazepines / sedatives5 products · 6%
First-generation cephalosporins5 products · 6%
Formulation footprint

Dosage forms

Tablet39 products
Suspension16 products
Injection13 products
Capsule11 products
Syrup1 products
How MedInfoBase classifies the portfolio

MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.

Portfolio leaders

Deepest brand families

Ranked by registered presentations · not sales
#1 CefrreCeftriaxone 7presentations 1 g, 2 g, 250 mg, 500 mg · Injection #2 ArractamLevetiracetam 5presentations 1000 mg, 250 mg, 500 mg, 750 mg · Tablet #3 RetaphalCephalexin 5presentations 125 mg/5 mL, 250 mg, 250 mg/5 mL, 500 mg · Suspension, Capsule #4 BydinMetronidazole 4presentations 200 mg/5 mL, 400 mg · Suspension, Tablet #5 OzymapOmeprazole 4presentations 20 mg, 40 mg · Tablet, Capsule #6 TimolParacetamol 4presentations 120 mg, 120 mg/5 mL, 250 mg/5 mL, 500 mg · Suspension, Tablet
Price intelligence

Unit-price positioning vs equivalent products

Same generic + strength + form + unit basis
Below market median5063% of comparable products
Near market median25within ±5% of median
Above market median45% of comparable products
Lowest-price equivalents6ties included
Company median price position -14.2% relative to the median unit price of like-for-like equivalent products.
Most competitively positioned examplesProducts with at least 3 market comparators
Tdpam 2 mgDiazepam · Tablet · 1000's PKR 0.22/tablet-75.4% vs market median Doxireta 50 mgPyridoxine HCl · Tablet · 20's PKR 1.85/tablet-58.3% vs market median Lumereta 80 mg + 480 mgArtemether + Lumefantrine · Tablet · 8's PKR 47.77/tablet-56.2% vs market median Arractam 500 mgLevetiracetam · Tablet · 10's PKR 50.38/tablet-47.6% vs market median Arractam 500 mgLevetiracetam · Tablet · 30's PKR 50.38/tablet-47.6% vs market median
How MedInfoBase calculates price position

Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.

Competitive landscape

Portfolio overlap

Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.

Mediate Pharmaceutical Pvt Ltd236 products · 90 generics 27shared generics Neutro Pharma (Pvt.) Ltd.,210 products · 97 generics 25shared generics SAFE PHARMACEUTICAL (PVT) LTD143 products · 53 generics 24shared generics Global Pharmaceuticals (Pvt.) Ltd.224 products · 80 generics 23shared generics Semos Pharmaceuticals PVT LTD104 products · 45 generics 23shared generics M/s. Genix Pharma (Pvt) Ltd.297 products · 97 generics 22shared generics
Regulatory & price activity

Observed database signals

Indexed registration numbers69Distinct registrations among indexed, published, presentation-validated products only
Verified price observations80
Products with a verified price80
Products with multiple price observations0
Source records with multiple versions80
Latest portfolio source check9 Aug 2026
Latest effective price date23 Jul 2026
Latest source observation23 Sep 2026

These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.

Company medicine portfolio

Medicine portfolio

73 unique registration(s) · 80 indexed presentation(s) · 2 additional source-observed presentation(s) · 3 registry-only registration(s)

This unified portfolio keeps three evidence lanes distinct: indexed MedInfoBase presentations, additional source-observed presentations, and registry-only registrations that are not otherwise represented. A registration number is not the same thing as a presentation, and source-observed rows are not counted as indexed. Source-only rows with a strength/form/pack contradiction remain visible as evidence but the conflicting field is held for normalization.

Reset
BrandGenericStrengthFormPackRegistrationSource-listed priceUnit pricePrice position
Acetofeine Paracetamol + Caffeine 500 mg + 65 mg Tablet 100's 116294 PKR 439.67 PKR 4.40/tablet Near median
Arelic Folic acid 5 mg Tablet 100's 098434 PKR 107.22 PKR 1.07/tablet 34% above median
Aretadine Loratadine 5 mg/5 mL Syrup 60ml 117649 PKR 56.75 PKR 0.95/mL 44% below median
Aripime 1gm InjectionRegistry verified Cefepime as HCl with L-Arginine eq. to Cefepime — — — 102723Official source ↗ No indexed price — —
Aripime 500mg InjectionRegistry verified Cefepime as HCl with L-Arginine eq. to Cefepime — — — 102722Official source ↗ No indexed price — —
Arractam Levetiracetam 250 mg Tablet 10's 116300 PKR 364.11 PKR 36.41/tablet 34% below median
Arractam Levetiracetam 750 mg Tablet 10's 116301 PKR 806.05 PKR 80.61/tablet 39% below median
Arractam Levetiracetam 1000 mg Tablet 10's 116302 PKR 1,007.56 PKR 100.76/tablet 37% below median
Arractam Levetiracetam 500 mg Tablet 30's 117743 PKR 1,511.34 PKR 50.38/tablet 48% below median
Arractam Levetiracetam 500 mg Tablet 10's 117743 PKR 503.78 PKR 50.38/tablet 48% below median
Arrefloxacin Levofloxacin 250 mg Tablet 10's 117635 PKR 289.53 PKR 28.95/tablet 40% below median
Arrefloxacin Levofloxacin 500 mg Tablet 10's 117844 PKR 481.78 PKR 48.18/tablet 39% below median
Arrepcin Ciprofloxacin 500 mg Tablet 10's 100670 PKR 345.23 PKR 34.52/tablet 19% below median
Arrepcin Ciprofloxacin 250 mg Tablet 10's 100671 PKR 208.74 PKR 20.87/tablet 18% below median
Arretaz Ceftazidime 500 mg Injection 1's 099797 PKR 231.22 PKR 231.22/vial/unit Near median
Arretaz Ceftazidime 1 g Injection 1's 102718 PKR 441.57 PKR 441.57/vial/unit Near median
Arretaz Ceftazidime 250 mg Injection 1's 102719 PKR 159.65 PKR 159.65/vial/unit Near median
Aryspride Risperidone 2 mg Tablet 10's 117642 PKR 225.83 PKR 22.58/tablet 39% below median
Aryspride Risperidone 4 mg Tablet 10's 117643 PKR 451.67 PKR 45.17/tablet 38% below median
Asko PlusSource observed Paracetamol — Tablet 100's 098030Official source ↗ No indexed price — —
Asko Plus Tablet Paracetamol +hyoscine N-butyl bromideSource observed — — — 100's 098030Official source ↗ No indexed price — —
Azereta Azithromycin 250 mg Capsule 6's 098435 PKR 245.68 PKR 40.95/capsule 17% below median
B-Profen Ibuprofen 200 mg/5 mL Suspension 90ml 083602 PKR 110.80 PKR 1.23/mL Near median
B-Profen Ibuprofen 100 mg/5 mL Suspension 90ml 083603 PKR 66.48 PKR 0.74/mL 22% below median
B-Profen Ibuprofen 100 mg/5 mL Suspension 120ml 083603 PKR 87.33 PKR 0.73/mL 23% below median
Bydin Metronidazole (Benzoate) 200 mg/5 mL Suspension 60ml 082346 PKR 59.09 PKR 0.98/mL Near median
Bydin Metronidazole 200 mg/5 mL Suspension 120ml 082346 PKR 110.80 PKR 0.92/mL Near median
Bydin Metronidazole 400 mg Tablet 200's 094040 PKR 583.68 PKR 2.92/tablet Near median
Bydin Metronidazole 400 mg Tablet 100's 094040 PKR 291.83 PKR 2.92/tablet Near median
Bydin Metronidazole 400 mg Tablet 20's 094040 PKR 58.37 PKR 2.92/tablet Near median
Cefrre Ceftriaxone 2 g IV injection 1's 099790 PKR 722.58 PKR 722.58/vial/unit 16% below median
Cefrre Ceftriaxone 1 g IV injection 1's 099791 PKR 515.44 PKR 515.44/vial/unit 17% below median
Cefrre Ceftriaxone 500 mg IV injection 1's 099792 PKR 272.97 PKR 272.97/vial/unit 13% below median
Cefrre Ceftriaxone 250 mg IV injection 1's 099793 PKR 162.18 PKR 162.18/vial/unit 13% below median
Cefrre Ceftriaxone 250 mg IM injection 1's 099794 PKR 162.18 PKR 162.18/vial/unit 17% below median
Cefrre Ceftriaxone 500 mg IM injection 1's 099795 PKR 272.97 PKR 272.97/vial/unit 17% below median
Cefrre Ceftriaxone 1 g IM injection 1's 102716 PKR 515.44 PKR 515.44/vial/unit 17% below median
Cefzed 500mg/500mg InjectionRegistry verified Cefoperazone as sodium, Sulbactum as sodium — — — 102717Official source ↗ No indexed price — —
Clareta Clarithromycin 500 mg Tablet 10's 100659 PKR 642.29 PKR 64.23/tablet 24% below median
Clareta Clarithromycin 250 mg Tablet 10's 100669 PKR 385.37 PKR 38.54/tablet 19% below median
Co-Deeprex Olanzapine + Fluoxetine 3 mg + 25 mg Capsule 30's 084286 PKR 515.75 PKR 17.19/capsule 5% below median
Co-Deeprex Olanzapine + Fluoxetine 3 mg + 25 mg Capsule 14's 084286 PKR 260.88 PKR 18.63/capsule 7% above median
Co-Deeprex Plus Olanzapine + Fluoxetine 6 mg + 25 mg Capsule 14's 084285 PKR 437.48 PKR 31.25/capsule Near median
Doxireta Pyridoxine HCl 50 mg Tablet 20's 117639 PKR 36.91 PKR 1.85/tablet 58% below median
Fe-betone Phenobarbital 30 mg Tablet 60's 087722 PKR 53.70 PKR 0.90/tablet Near median
Fe-betone Phenobarbital 30 mg Tablet 100's 087722 PKR 89.50 PKR 0.90/tablet Near median
Lumereta Artemether + Lumefantrine 20 mg + 120 mg Tablet 16's 117633 PKR 370.60 PKR 23.16/tablet 42% below median
Lumereta Artemether + Lumefantrine 80 mg + 480 mg Tablet 8's 117634 PKR 382.18 PKR 47.77/tablet 56% below median
Lumereta DS Artemether + Lumefantrine 40 mg + 240 mg Tablet 10's 117839 PKR 359.02 PKR 35.90/tablet 44% below median
Midzee Midazolam 7.5 mg Tablet 10's 102678 PKR 144.52 PKR 14.45/tablet 40% above median
MedInfoBase company-intelligence methodology

This page is generated from MedInfoBase medicine, generic, company, price and official-source records. Unverified third-party discovery records are retained internally for coverage auditing and are not published as company registrations. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official-source prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.

Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.

Cite this record

Manufacturer record
MedInfoBase. (2026). Arreta Pharmaceuticals (Pvt.) Ltd — registered product portfolio in Pakistan [Data set]. MedInfoBase. Retrieved September 25, 2026, from https://medinfobase.com/company/arreta-pharmaceuticals-pvt-ltd/
Download .RIS Download .BIB EndNote, Zotero, Mendeley, RefWorks

Records change over time. Please cite the access date so readers can locate the version you used.